Eliem Therapeutics Inc
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Eliem Therapeutics Inc (ELYM) - Net Assets
Latest net assets as of June 2024: $222.28 Million USD
Based on the latest financial reports, Eliem Therapeutics Inc (ELYM) has net assets worth $222.28 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($226.02 Million) and total liabilities ($3.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $222.28 Million |
| % of Total Assets | 98.34% |
| Annual Growth Rate | 51.15% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 297.58 |
Eliem Therapeutics Inc - Net Assets Trend (2019–2023)
This chart illustrates how Eliem Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Eliem Therapeutics Inc (2019–2023)
The table below shows the annual net assets of Eliem Therapeutics Inc from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $107.60 Million | -16.41% |
| 2022-12-31 | $128.72 Million | -23.02% |
| 2021-12-31 | $167.20 Million | +675.24% |
| 2020-12-31 | $21.57 Million | +4.64% |
| 2019-12-31 | $20.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eliem Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14851100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $-2.00K | 0.00% |
| Other Components | $263.58 Million | 244.96% |
| Total Equity | $107.60 Million | 100.00% |
Eliem Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Eliem Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emerging Display Technologies Corp
TW:3038
|
$81.09 Million |
|
F3 Uranium Corp.
OTCQB:FUUFF
|
$81.10 Million |
|
Elektrotim SA
WAR:ELT
|
$81.11 Million |
|
Bastide Le Confort Médical SA
PA:BLC
|
$81.11 Million |
|
Forest Water Environmental Eng Co Ltd
TW:8473
|
$81.07 Million |
|
FOCUSRITE PLC LS -001
F:0FO
|
$81.07 Million |
|
Indoco Remedies Limited
NSE:INDOCO
|
$81.05 Million |
|
Amulaire Thermal Technology
TW:2241
|
$81.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eliem Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 128,715,000 to 107,599,000, a change of -21,116,000 (-16.4%).
- Net loss of 35,119,000 reduced equity.
- Other comprehensive income increased equity by 356,000.
- Other factors increased equity by 13,647,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.12 Million | -32.64% |
| Other Comprehensive Income | $356.00K | +0.33% |
| Other Changes | $13.65 Million | +12.68% |
| Total Change | $- | -16.41% |
Book Value vs Market Value Analysis
This analysis compares Eliem Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.78x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.95x to 0.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.78 | $3.09 | x |
| 2020-12-31 | $0.82 | $3.09 | x |
| 2021-12-31 | $6.37 | $3.09 | x |
| 2022-12-31 | $4.89 | $3.09 | x |
| 2023-12-31 | $3.99 | $3.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eliem Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-32.64%) is above the historical average (-33.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -18.42% | 0.00% | 0.00x | 1.04x | $-5.86 Million |
| 2020 | -53.37% | 0.00% | 0.00x | 1.14x | $-13.67 Million |
| 2021 | -28.40% | 0.00% | 0.00x | 1.04x | $-64.20 Million |
| 2022 | -35.24% | 0.00% | 0.00x | 1.05x | $-58.22 Million |
| 2023 | -32.64% | 0.00% | 0.00x | 1.03x | $-45.88 Million |
Industry Comparison
This section compares Eliem Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eliem Therapeutics Inc (ELYM) | $222.28 Million | -18.42% | 0.02x | $81.07 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |